Owen LaRue LLC Has $581,000 Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Owen LaRue LLC reduced its stake in Eli Lilly and Company by 77.4% in the second quarter, now holding 745 shares valued at approximately $581,000.
• Analysts are mixed on Eli Lilly's stock, with Morgan Stanley maintaining an "overweight" rating and a target price of $1,135.00, while other firms have downgraded their ratings.
• Eli Lilly reported $6.31 earnings per share for the last quarter, exceeding estimates, and has set a fiscal year 2025 guidance of $21.750-23.000 EPS.

Owen LaRue LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 77.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 745 shares of the company's stock after selling 2,548 shares during the period. Owen LaRue LLC's holdings in Eli Lilly and Company were worth $581,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Duquesne Family Office LLC boosted its holdings in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after buying an additional 32,640 shares during the period. Corient IA LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $570,000. LS Investment Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after buying an additional 40 shares during the period. Cutter Capital Management LP bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $14,866,000. Finally, Prism Advisors Inc. bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $207,000. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $939.61.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $713.87 on Friday. The company has a 50 day moving average of $735.09 and a 200-day moving average of $767.88. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market cap of $675.65 billion, a PE ratio of 46.66, a price-to-earnings-growth ratio of 1.03 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm posted $3.92 EPS. The firm's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last 90 days. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.